A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients | MicrobiomeTrials← Back to trialsNCT07424625
A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-07Est. Completion: 2027-02
Enrollment target: 250 participants Locations- Mayo Clinic, Rochester, Minnesota, United States
Other microbiome trials you might be interested in
Metabolic AcidosisAcute Kidney Injury
Severe metabolic acidemia in the critically ill (pH equal or less than 7.20; PaCO2 equal or less than 45mmHg and bicarbo…
Montpellier, FranceCompleted Dec 19, 2023
Alcohol Use DisorderKetosis
This is a randomized, double-blind, crossover trial to evaluate the immediate effects of a nutritional ketone supplement…
Philadelphia, United StatesEst. completion Jan 1, 2030